Agenus Inc (AGEN)
13.05
+0.51
(+4.07%)
USD |
NASDAQ |
May 03, 16:00
13.05
0.00 (0.00%)
After-Hours: 20:00
Agenus Enterprise Value: 211.42M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 211.42M |
| May 01, 2024 | 226.50M |
| April 30, 2024 | 202.62M |
| April 29, 2024 | 216.02M |
| April 26, 2024 | 193.61M |
| April 25, 2024 | 122.60M |
| April 24, 2024 | 104.17M |
| April 23, 2024 | 84.06M |
| April 22, 2024 | 69.61M |
| April 19, 2024 | 59.98M |
| April 18, 2024 | 52.85M |
| April 17, 2024 | 61.86M |
| April 16, 2024 | 80.71M |
| April 15, 2024 | 84.90M |
| April 12, 2024 | 119.46M |
| April 11, 2024 | 134.54M |
| April 10, 2024 | 135.63M |
| April 09, 2024 | 152.56M |
| April 08, 2024 | 143.76M |
| April 05, 2024 | 159.76M |
| April 04, 2024 | 160.68M |
| April 03, 2024 | 170.82M |
| April 02, 2024 | 163.24M |
| April 01, 2024 | 194.87M |
| March 28, 2024 | 191.73M |
| Date | Value |
|---|---|
| March 27, 2024 | 181.84M |
| March 26, 2024 | 173.46M |
| March 25, 2024 | 182.68M |
| March 22, 2024 | 177.53M |
| March 21, 2024 | 184.27M |
| March 20, 2024 | 181.09M |
| March 19, 2024 | 184.44M |
| March 18, 2024 | 170.65M |
| March 15, 2024 | 174.97M |
| March 14, 2024 | 199.98M |
| March 13, 2024 | 224.65M |
| March 12, 2024 | 229.09M |
| March 11, 2024 | 230.85M |
| March 08, 2024 | 229.47M |
| March 07, 2024 | 228.79M |
| March 06, 2024 | 228.31M |
| March 05, 2024 | 217.21M |
| March 04, 2024 | 221.16M |
| March 01, 2024 | 212.38M |
| February 29, 2024 | 216.33M |
| February 28, 2024 | 248.76M |
| February 27, 2024 | 259.38M |
| February 26, 2024 | 238.50M |
| February 23, 2024 | 221.16M |
| February 22, 2024 | 218.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
52.85M
Minimum
Apr 18 2024
1.453B
Maximum
Aug 30 2021
484.05M
Average
448.00M
Median
Enterprise Value Benchmarks
| Protalix BioTherapeutics Inc | 60.43M |
| InfuSystems Holdings Inc | 186.65M |
| PAVmed Inc | 77.91M |
| Allogene Therapeutics Inc | 53.51M |
| Pfizer Inc | 215.28B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.29M |
| Revenue (Quarterly) | 83.80M |
| Total Expenses (Quarterly) | 88.16M |
| EPS Diluted (Quarterly) | -2.40 |
| Gross Profit Margin (Quarterly) | 20.07% |
| Profit Margin (Quarterly) | -55.24% |
| Earnings Yield | -107.3% |
| Normalized Earnings Yield | -107.54 |